📰 BloombergBloombergCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:00:48时区推断·⟳ 抓取 20:14:23·⚡ 决策 07-21 20:26:28 +12m05s·98.3 天前
Barington再度施压Chemed进行战略评估、降本和董事会更新
本次是激进投资者推动战略评估、利润率改善和董事会更新，方向上利多Chemed（CHE.US）的治理和潜在价值释放。
📄 原文Bloomberg↗ 原文
Activist Barington Pushes Chemed for Strategic Review, Cost Cuts Activist investor Barington Capital Group is ramping u…
不做 Chemed（CHE.US）
Barington维权主题6月已公开，当前仅为升级施压且持股约0.43%、无公司采纳或交易方案；Chemed（CHE.US）近20日已涨17.74%并接近52周高点，新增edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Bloomberg Law已报道Barington建仓Chemed并建议加入新董事，说明核心维权主题并非7月21日首次出现。
- Barington一季度持有Chemed约57100股，占流通股约0.43%，持股比例偏小，施压强度有限。
- Bloomberg报道称Barington升级施压，要求战略评估、降本和董事会更新，但未出现公司采纳或正式交易方案。市场反应:Chemed（CHE.US）截至12:24 UTC报513.68美元，较前收盘涨0.72%，近20日涨17.74%。
关键理由
- 本次是激进投资者推动战略评估、利润率改善和董事会更新，方向上利多Chemed（CHE.US）的治理和潜在价值释放。
- 但Barington上月已公开建仓并提出董事候选，本条更像同一维权行动的升级转述，而非首次催化。
- Barington持股仅约0.43%，Chemed（CHE.US）过去20个交易日已涨17.74%且接近52周高点，短线新增edge不足。
主要风险
- 若公司随后宣布正式战略评估、剥离Vitas或Roto-Rooter、或接受董事提名，才可能形成新的可交易催化。
- 当前仅为投资者施压信，未披露公司采纳行动或确定交易方案，容易被市场视为已知治理噪音。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中同一事件的有效增量报道，未能提供比公开Bloomberg更强的新增催化证据。
检索:Chemed Barington Capital strategic review cost cuts board refresh June 2026 - 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中能改变方向的近期反向证据，但也未提供可量化的战略评估或降本落地线索。
检索:Chemed Vitas Roto-Rooter recent risks hospice Medicare reimbursement 2026
工具调用 · 历史记录,结果未知(4 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- search_case_library · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,553 字
Activist Barington Pushes Chemed for Strategic Review, Cost Cuts
Activist investor Barington Capital Group is ramping up its campaign against Chemed Corp., saying the holding company for a hospice service and a plumbing business should conduct a strategic review and refresh its board.
Barington Chairman and Chief Executive Officer James Mitarotonda said in a letter to Chemed’s board that the company has two “outstanding businesses whose value is not being maximized.” Mitarotonda wrote in the letter reviewed by Bloomberg News that Chemed has been underperforming its peer group and the broader market, while its management and board have responded to challenges “with insufficient urgency.”
“Very few companies can point to a record of this quality, and the board and Chemed’s Chief Executive Officer Kevin McNamara deserve significant credit for these accomplishments,” Mitarotonda wrote. “Unfortunately, the company’s recent performance no longer reflects either the quality of its businesses or its past legacy of success.”
Barington said it has held talks with McNamara and Michael Witzeman, Chemed’s chief financial officer. A representative for Chemed didn’t immediately respond to a request for comment.
Cincinnati-based Chemed has two units: Hospice provider Vitas Healthcare and plumbing and drain-cleaning services firm Roto-Rooter.
Barington is pushing the board to perform a strategic review and formulate plans to improve profitability, including addressing whether the current multi-business structure has contributed to the “under-investment” in Roto-Rooter.
The activist is also calling the board to cut costs, starting with perks such as the CEO’s personal use of company aircraft, tickets for sporting events and club membership.
Barington argues that Chemed needs to rebuild its executive compensation program after shareholders voted against an advisory measure on it. The company also needs to refresh its board, the activist said, adding that it has recommended a new director candidate.
“Simply put, we do not believe that Chemed has become a weaker company — in our opinion it has become a less ambitious one that suffers from a lack of accountability and effective oversight,” Mitarotonda wrote.
Barington disclosed its campaign against Chemed last month. The activist holds about 0.43% of Chemed’s outstanding shares, according to regulatory filings for the quarter ended March 31.
Shares of Chemed, which dropped 19% in 2025, have gained 20% in New York this year, giving the company a market value of about $6.9 billion.
Activist investor Barington Capital Group is ramping up its campaign against Chemed Corp., saying the holding company for a hospice service and a plumbing business should conduct a strategic review and refresh its board.
Barington Chairman and Chief Executive Officer James Mitarotonda said in a letter to Chemed’s board that the company has two “outstanding businesses whose value is not being maximized.” Mitarotonda wrote in the letter reviewed by Bloomberg News that Chemed has been underperforming its peer group and the broader market, while its management and board have responded to challenges “with insufficient urgency.”
“Very few companies can point to a record of this quality, and the board and Chemed’s Chief Executive Officer Kevin McNamara deserve significant credit for these accomplishments,” Mitarotonda wrote. “Unfortunately, the company’s recent performance no longer reflects either the quality of its businesses or its past legacy of success.”
Barington said it has held talks with McNamara and Michael Witzeman, Chemed’s chief financial officer. A representative for Chemed didn’t immediately respond to a request for comment.
Cincinnati-based Chemed has two units: Hospice provider Vitas Healthcare and plumbing and drain-cleaning services firm Roto-Rooter.
Barington is pushing the board to perform a strategic review and formulate plans to improve profitability, including addressing whether the current multi-business structure has contributed to the “under-investment” in Roto-Rooter.
The activist is also calling the board to cut costs, starting with perks such as the CEO’s personal use of company aircraft, tickets for sporting events and club membership.
Barington argues that Chemed needs to rebuild its executive compensation program after shareholders voted against an advisory measure on it. The company also needs to refresh its board, the activist said, adding that it has recommended a new director candidate.
“Simply put, we do not believe that Chemed has become a weaker company — in our opinion it has become a less ambitious one that suffers from a lack of accountability and effective oversight,” Mitarotonda wrote.
Barington disclosed its campaign against Chemed last month. The activist holds about 0.43% of Chemed’s outstanding shares, according to regulatory filings for the quarter ended March 31.
Shares of Chemed, which dropped 19% in 2025, have gained 20% in New York this year, giving the company a market value of about $6.9 billion.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。